Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Abstract:

:Median survival of patients with malignant glioma (MG) from time of diagnosis is approximately 1 year, despite surgery, irradiation and conventional chemotherapy. Improving patient outcome relies on our ability to develop more effective therapies that are directed against the unique molecular aberrations within a patient's tumor. Such molecularly targeted therapies may provide novel treatments that are more effective than conventional chemotherapeutics. Recently developed therapeutic strategies have focused on targeting several core glioma signaling pathways, including pathways mediated by growth-factors, PI3K/Akt/PTEN/mTOR, Ras/Raf/MEK/MAPK and other vital pathways. However, given the molecular diversity, heterogeneity and diverging and converging signaling pathways associated with MG, it is unlikely that any single agent will have efficacy in more than a subset of tumors. Overcoming these therapeutic barriers will require multiple agents that can simultaneously inhibit these processes, providing a rationale for combination therapies. This review summarizes the currently implemented single-agent and combination molecularly targeted therapies for MG.

journal_name

Expert Rev Neurother

authors

Thaker NG,Pollack IF

doi

10.1586/ern.09.116

subject

Has Abstract

pub_date

2009-12-01 00:00:00

pages

1815-36

issue

12

eissn

1473-7175

issn

1744-8360

journal_volume

9

pub_type

杂志文章,评审
  • Update on emerging therapies for multiple sclerosis.

    abstract::The American Academy of Neurology is an international professional organization of more than 22,000 neurologists and neuroscience professionals. This year the annual meeting was held in Toronto, ON, Canada. A large number of scientific sessions presented numerous advances in the diagnosis, molecular pathogenesis and t...

    journal_title:Expert review of neurotherapeutics

    pub_type:

    doi:10.1586/ern.10.98

    authors: Yiu EM,Banwell B

    更新日期:2010-08-01 00:00:00

  • Neurostimulation in primary headache syndromes.

    abstract::Neurostimulation therapy involves the use of peripheral or central nerve electrical stimulation approaches for the treatment of medically intractable headache. Currently, for peripheral stimulation the main approach is that of occipital nerve stimulation, while for central stimulation deep-brain approaches with the ta...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.12.1785

    authors: Goadsby PJ

    更新日期:2007-12-01 00:00:00

  • Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan.

    abstract:INTRODUCTION:Chronic inflammatory neuropathies are disorders caused by an immune response to peripheral nerve. They include chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and neuropathy associated with anti-MAG IgM monoclonal gammopathy and other less frequent neurop...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1340832

    authors: Nobile-Orazio E,Gallia F,Terenghi F,Bianco M

    更新日期:2017-08-01 00:00:00

  • Voxel-based morphometry in Alzheimer's disease.

    abstract::Recent morphometric MRI studies have investigated brain volume abnormalities associated with the diagnosis of Alzheimer's disease (AD) using voxel-based morphometry (VBM). This technique allows the assessment of gray matter volumes in subjects with AD or related conditions compared with healthy controls in an automate...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.11.1691

    authors: Busatto GF,Diniz BS,Zanetti MV

    更新日期:2008-11-01 00:00:00

  • Potential new complication in drug therapy development for amyotrophic lateral sclerosis.

    abstract:INTRODUCTION:Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by motor neuron degeneration in the brain and spinal cord. Treatment development for ALS is complicated by complex underlying disease factors. Areas covered: Numerous tested drug compounds have shown no benefits in ALS p...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2016.1207530

    authors: Garbuzova-Davis S,Thomson A,Kurien C,Shytle RD,Sanberg PR

    更新日期:2016-12-01 00:00:00

  • Cannabis and multiple sclerosis.

    abstract:INTRODUCTION:Patients with multiple sclerosis (MS) may suffer from spasticity and pain during their disease course. Baclofen, dantrolene, diazepam and gabapentin have been used as first-line options to treat these conditions, with modest results. Medical use of marijuana smoking has bypassed traditional clinical trials...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1776610

    authors: Fragoso YD,Carra A,Macias MA

    更新日期:2020-08-01 00:00:00

  • Attention-deficit/hyperactivity disorder and the dopaminergic hypotheses.

    abstract::Attention-deficit/hyperactivity disorder (ADHD) is a common psychiatric condition that affects approximately 5.3% of children worldwide. This disorder is defined by a combination of symptoms of inattention and hyperactivity/impulsivity. Diagnosis is based on impairment in these two domains determining several problems...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.17

    authors: Genro JP,Kieling C,Rohde LA,Hutz MH

    更新日期:2010-04-01 00:00:00

  • Disease-specific therapy of idiopathic inflammatory demyelinating disorders.

    abstract::Central nervous system idiopathic inflammatory demyelinating disorders are a heterogenous group of diseases that share inflammation and demyelination as key features. Although the exact pathophysiology remains to be fully unveiled, these conditions are challenging to clinicians who seek specific therapeutic options fo...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.101

    authors: Khoshnam M,Freedman MS

    更新日期:2012-09-01 00:00:00

  • Effects of surgical resection and adjuvant therapy on pediatric intracranial ependymomas.

    abstract::The optimal therapy of pediatric ependymomas is controversial. The benefit of surgical resection is widely accepted, but the role of adjuvant therapy is subject to debate. Due to the relatively low survival rates of ependymoma patients, as well as the tumor's high recurrence rates, further research into the efficacy o...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.4.465

    authors: Krieger MD,Bowen IE

    更新日期:2005-07-01 00:00:00

  • Nusinersen for the treatment of spinal muscular atrophy.

    abstract:INTRODUCTION:Spinal muscular atrophy (SMA) is an autosomal recessive degenerative neuromuscular disorder characterized by loss of spinal motor neurons leading to muscle weakness. This review article focuses on a novel antisense oligonucleotide treatment, first ever approved for SMA (nusinersen, SpinrazaTM) and describe...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1364159

    authors: Chiriboga CA

    更新日期:2017-10-01 00:00:00

  • Cardiovascular effects of antipsychotics.

    abstract::There is great concern over cardiovascular disease in the schizophrenic population owing to the high incidence of cardiovascular mortality. Increased cardiovascular mortality is related to lifestyle choices (e.g., smoking and sedentary lifestyle) and a high prevalence of comorbid medical conditions, including dyslipid...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.7.829

    authors: Michelsen JW,Meyer JM

    更新日期:2007-07-01 00:00:00

  • Systemic thrombolytic therapy of acute ischemic stroke with rtPA.

    abstract::Systemic thrombolysis with recombinant tissue plasminogen activator is the first therapy proven to be effective in acute ischemic stroke. Nevertheless, its efficacy and feasibility are still a matter of debate. Much of this debate derives from uncertainties regarding patient eligibility and problems implementing this ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2.2.187

    authors: Koennecke HC

    更新日期:2002-03-01 00:00:00

  • An update on the comorbidity of ADHD and ASD: a focus on clinical management.

    abstract::Attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) commonly co-occur. With the DSM-5, clinicians are permitted to make an ASD diagnosis in the context of ADHD. In earlier versions of the DSM, this was not acceptable. Both ASD and ADHD are reported to have had substantial increases in pr...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2016.1146591

    authors: Antshel KM,Zhang-James Y,Wagner KE,Ledesma A,Faraone SV

    更新日期:2016-01-01 00:00:00

  • Cognitive-behavioral therapy: what benefits can it offer people with multiple sclerosis?

    abstract::Cognitive-behavioral therapy (CBT) originated as a treatment for emotional disorders. However, it is increasingly used to help people with chronic illnesses manage symptoms and improve psychosocial outcomes, such as depression and quality of life. In this article, we focus on uses of CBT in patients with multiple scle...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.111

    authors: Dennison L,Moss-Morris R

    更新日期:2010-09-01 00:00:00

  • Deep brain stimulation for the treatment of uncommon tremor syndromes.

    abstract:INTRODUCTION:Deep brain stimulation (DBS) has become a standard therapy for the treatment of select cases of medication refractory essential tremor and Parkinson's disease however the effectiveness and long-term outcomes of DBS in other uncommon and complex tremor syndromes has not been well established. Traditionally,...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2016.1194756

    authors: Ramirez-Zamora A,Okun MS

    更新日期:2016-08-01 00:00:00

  • Treatment of dystonia.

    abstract::Dystonia may be a sign or symptom, that is comprised of complex abnormal and dynamic movements of different etiologies. A specific cause is identified in approximately 28% of patients, which only occasionally results in specific treatment. In most cases, treatment is symptomatic and designed to relieve involuntary mov...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.6.863

    authors: Bhidayasiri R,Tarsy D

    更新日期:2006-06-01 00:00:00

  • Pharmacotherapy for social anxiety disorder: a systematic review.

    abstract::Social anxiety disorder (SAD) is a prevalent, disabling disorder. We aimed to assess the effects of pharmacotherapy for SAD and to determine whether particular classes of medication are more effective and/or better tolerated than others. A systematic review and meta-analysis was conducted of all published and unpublis...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.2.235

    authors: Ipser JC,Kariuki CM,Stein DJ

    更新日期:2008-02-01 00:00:00

  • Cannabinoids and pain relief.

    abstract::Understanding of the structure and function of the endocannabinoid system is rapidly evolving. Physiological and pharmacological manipulations based on cannabinoid receptors, ligands and endocannabinoids have explained some medicinal attributes of cannabinoids as used across the world for thousands of years. Plant-der...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.1.1.92

    authors: Holdcroft A,Patel P

    更新日期:2001-09-01 00:00:00

  • Clinical, etiological and therapeutic aspects of cerebral folate deficiency.

    abstract::Cerebral folate deficiency is defined as any neurological condition associated with low cerebrospinal fluid folate concentrations. It is becoming increasingly associated with several neurological diseases, either genetic or environmental. Treatment of cerebral folate deficiency by folate supplementation is generally e...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1055322

    authors: Molero-Luis M,Serrano M,O'Callaghan MM,Sierra C,Pérez-Dueñas B,García-Cazorla A,Artuch R

    更新日期:2015-01-01 00:00:00

  • Retinoic acid as a therapeutic option in Alzheimer's disease: a focus on cholinergic restoration.

    abstract::Retinoic acid is a potent cell differentiating factor, which through its nuclear receptors affects a vast range of promoter sites in brain neuronal and glial cells in every step of embryonic and postnatal life. Its capacities, facilitating maturation of neurotransmitter phenotype in different groups of neurons, pave t...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1008456

    authors: Szutowicz A,Bielarczyk H,Jankowska-Kulawy A,Ronowska A,Pawełczyk T

    更新日期:2015-03-01 00:00:00

  • Cognitive changes in multiple sclerosis.

    abstract::Cognitive dysfunction (CD) affects 40-65% of multiple sclerosis (MS) patients and can have a great functional impact. It can be detected in all the disease phenotypes from the early stages of the disease and tends to progress over time. Memory, complex attention, information processing speed and executive functions ar...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.10.1585

    authors: Amato MP,Zipoli V,Portaccio E

    更新日期:2008-10-01 00:00:00

  • Epilepsy in the elderly.

    abstract::Epilepsy is the most common serious neurological disorder in the elderly after stroke and dementia. It may be more important for elderly people because it is intermittent and unpredictable. There is no reliable diagnostic test and so its diagnosis and management requires clinical acumen and experience. The situation i...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.170

    authors: Johnston A,Smith PE

    更新日期:2010-12-01 00:00:00

  • Pseudotumor cerebri presenting as headache.

    abstract::Pseudotumor cerebri (PTC) is characterized by intracranial hypertension without ventriculomegaly, in the absence of a mass lesion or meningeal process. When there is no secondary cause, it is termed 'idiopathic intracranial hypertension'. Headache is the most common symptom of PTC, present in over 90% of patients. The...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.3.397

    authors: Friedman DI

    更新日期:2008-03-01 00:00:00

  • Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication.

    abstract::Alzheimer's disease (AD) is a prevalent and currently incurable brain disease whose impact will continue to rise as the population ages. With limited treatment options, a variety of experimental therapies are currently in clinical trials. EVP-6124 (encenicline) is an α7 nicotinic acetylcholine receptor partial agonist...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.995639

    authors: Deardorff WJ,Shobassy A,Grossberg GT

    更新日期:2015-01-01 00:00:00

  • Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?

    abstract::Evaluation of: Segal BM, Constantinescu CS, Raychaudhuri A et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a Phase II, double-blind, placebo-controlled, randomized, dose-ranging study. Lancet Neurol. 7, 796-804 (2008). ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.9.3.319

    authors: Longbrake EE,Racke MK

    更新日期:2009-03-01 00:00:00

  • Light and chemical control of neuronal circuits: possible applications in neurotherapy.

    abstract::Millions of people worldwide suffer from diseases that result from a failure of central pathways to regulate behavioral and physiological processes. Advances in genetics and pharmacology have already allowed us to appreciate that rather than this dysregulation being systemic throughout the brain, it is usually rooted ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.948850

    authors: Whittle AJ,Walsh J,de Lecea L

    更新日期:2014-09-01 00:00:00

  • Special biological issues in the management of women with schizophrenia.

    abstract::Schizophrenia is a debilitating and pervasive mental illness with devastating effects on psychological, cognitive and social wellbeing, and for which current treatment options are far from ideal. Gender differences and the influence of the female reproductive life cycle on the onset, course and symptoms of schizophren...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.62

    authors: Kulkarni J,Gavrilidis E,Hayes E,Heaton V,Worsley R

    更新日期:2012-07-01 00:00:00

  • Interferon-beta1b in multiple sclerosis.

    abstract::In 1993, interferon (IFN)-beta(1b) for subcutaneous injection became the first US FDA-approved immunomodulatory treatment for multiple sclerosis, a chronic inflammatory disease of the CNS. In this review of IFN-beta(1b), we first present a short introduction to multiple sclerosis and currently available therapeutics. ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.3.227

    authors: Buttmann M,Rieckmann P

    更新日期:2007-03-01 00:00:00

  • Acetyl-l-carnitine as a possible therapy for Alzheimer's disease.

    abstract::Alterations have been demonstrated in membrane phospholipid metabolism in Alzheimer's disease. Alterations in membrane phospholipid metabolite levels have been observed by 31P magnetic resonance spectroscopy 4 years before onset of cognitive changes. Implications of phospholipid membrane changes in Alzheimer's disease...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2.5.647

    authors: Pettegrew JW,McClure RJ

    更新日期:2002-09-01 00:00:00

  • Dual tasking in Parkinson's disease: should we train hazardous behavior?

    abstract::Dual-task (DT) circumstances aggravate gait disorders in Parkinson's disease (PD) and are associated with an increased risk of falling and reduced functional mobility. Clinical rehabilitation guidelines for PD consider DT interventions as potentially hazardous and recommend avoiding them in daily life. The current art...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1077116

    authors: Strouwen C,Molenaar EA,Münks L,Keus SH,Bloem BR,Rochester L,Nieuwboer A

    更新日期:2015-01-01 00:00:00